These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 21725367)

  • 1. Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis.
    Smirnova T; Zhou ZN; Flinn RJ; Wyckoff J; Boimel PJ; Pozzuto M; Coniglio SJ; Backer JM; Bresnick AR; Condeelis JS; Hynes NE; Segall JE
    Oncogene; 2012 Feb; 31(6):706-15. PubMed ID: 21725367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
    Hutcheson IR; Knowlden JM; Hiscox SE; Barrow D; Gee JM; Robertson JF; Ellis IO; Nicholson RI
    Breast Cancer Res; 2007; 9(4):R50. PubMed ID: 17686159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heregulin inhibits proliferation via ERKs and phosphatidyl-inositol 3-kinase activation but regulates urokinase plasminogen activator independently of these pathways in metastatic mammary tumor cells.
    Puricelli L; Proietti CJ; Labriola L; Salatino M; Balañá ME; Aguirre Ghiso J; Lupu R; Pignataro OP; Charreau EH; Bal de Kier Joffé E; Elizalde PV
    Int J Cancer; 2002 Aug; 100(6):642-53. PubMed ID: 12209601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.
    Yen L; Cao Z; Wu X; Ingalla ER; Baron C; Young LJ; Gregg JP; Cardiff RD; Borowsky AD; Sweeney C; Carraway KL
    Cancer Res; 2006 Dec; 66(23):11279-86. PubMed ID: 17145873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of mitogen-activated protein kinase and phosphoinositide 3'-kinase in ErbB2/ErbB3 coreceptor-mediated heregulin signaling.
    Vijapurkar U; Kim MS; Koland JG
    Exp Cell Res; 2003 Apr; 284(2):291-302. PubMed ID: 12651161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.
    Kim A; Liu B; Ordonez-Ercan D; Alvarez KM; Jones LD; McKimmey C; Edgerton SM; Yang X; Thor AD
    Breast Cancer Res; 2005; 7(5):R708-18. PubMed ID: 16168116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulation of beta1-integrin function by epidermal growth factor and heregulin-beta has distinct requirements for erbB2 but a similar dependence on phosphoinositide 3-OH kinase.
    Adelsman MA; McCarthy JB; Shimizu Y
    Mol Biol Cell; 1999 Sep; 10(9):2861-78. PubMed ID: 10473632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
    Young CD; Pfefferle AD; Owens P; Kuba MG; Rexer BN; Balko JM; Sánchez V; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL
    Cancer Res; 2013 Jul; 73(13):4075-85. PubMed ID: 23633485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Ste20-like kinase SLK is required for ErbB2-driven breast cancer cell motility.
    Roovers K; Wagner S; Storbeck CJ; O'Reilly P; Lo V; Northey JJ; Chmielecki J; Muller WJ; Siegel PM; Sabourin LA
    Oncogene; 2009 Aug; 28(31):2839-48. PubMed ID: 19525980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heregulin-dependent activation of phosphoinositide 3-kinase and Akt via the ErbB2/ErbB3 co-receptor.
    Hellyer NJ; Kim MS; Koland JG
    J Biol Chem; 2001 Nov; 276(45):42153-61. PubMed ID: 11546794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ErbB3-dependent motility and intravasation in breast cancer metastasis.
    Xue C; Liang F; Mahmood R; Vuolo M; Wyckoff J; Qian H; Tsai KL; Kim M; Locker J; Zhang ZY; Segall JE
    Cancer Res; 2006 Feb; 66(3):1418-26. PubMed ID: 16452197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function.
    Ishizawar RC; Miyake T; Parsons SJ
    Oncogene; 2007 May; 26(24):3503-10. PubMed ID: 17173075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer.
    Stern DF
    J Mammary Gland Biol Neoplasia; 2008 Jun; 13(2):215-23. PubMed ID: 18454306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4.
    Lee H; Akita RW; Sliwkowski MX; Maihle NJ
    Cancer Res; 2001 Jun; 61(11):4467-73. PubMed ID: 11389077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heregulin-induced activation of ErbB3 by EGFR tyrosine kinase activity promotes tumor growth and metastasis in melanoma cells.
    Ueno Y; Sakurai H; Tsunoda S; Choo MK; Matsuo M; Koizumi K; Saiki I
    Int J Cancer; 2008 Jul; 123(2):340-347. PubMed ID: 18398842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation of a Shc binding site tyrosine residue in ErbB3/HER3 blocks heregulin-dependent activation of mitogen-activated protein kinase.
    Vijapurkar U; Cheng K; Koland JG
    J Biol Chem; 1998 Aug; 273(33):20996-1002. PubMed ID: 9694850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heregulin-ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells.
    Yarar D; Lahdenranta J; Kubasek W; Nielsen UB; MacBeath G
    Mol Cancer Ther; 2015 Sep; 14(9):2072-80. PubMed ID: 26116360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines.
    Knowlden JM; Gee JM; Barrow D; Robertson JF; Ellis IO; Nicholson RI; Hutcheson IR
    Breast Cancer Res; 2011 Sep; 13(5):R93. PubMed ID: 21939528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uncoupling of PI3K from ErbB3 impairs mammary gland development but does not impact on ErbB2-induced mammary tumorigenesis.
    Lahlou H; Müller T; Sanguin-Gendreau V; Birchmeier C; Muller WJ
    Cancer Res; 2012 Jun; 72(12):3080-90. PubMed ID: 22665265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer.
    Tao JJ; Castel P; Radosevic-Robin N; Elkabets M; Auricchio N; Aceto N; Weitsman G; Barber P; Vojnovic B; Ellis H; Morse N; Viola-Villegas NT; Bosch A; Juric D; Hazra S; Singh S; Kim P; Bergamaschi A; Maheswaran S; Ng T; Penault-Llorca F; Lewis JS; Carey LA; Perou CM; Baselga J; Scaltriti M
    Sci Signal; 2014 Mar; 7(318):ra29. PubMed ID: 24667376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.